• OncoDNA

  Participated · Equity · Sep 2016

  OncoDNA combines advanced testing of clinically relevant cancer biomarkers (DNA, RNA and protein) from solid and liquid biopsies with a proprietary cancer treatment knowledge database to deliver one‑stop analysis and interpretation services. Its web‑based OncoKDM software processes raw NGS data to generate clinical insights such as treatment options and clinical‑trial matches for oncologists. The company also licenses its interpretation software to molecular laboratories and collaborates with biopharma on clinical‑trial design, enrollment and assessment. OncoDNA completed a €19 million Series B equity financing to support rapid international growth, accelerate software development and expand hiring. The company aims to become the European leader in oncogenomic data interpretation and to connect molecular laboratories to its advanced interpretation tools. OncoDNA is based in Gosselies, Belgium, employs 50 people across four countries, has an international network of 35 distributors covering approximately 50 countries, and collaborates with a subcontracted laboratory of about 300 collaborators. OncoDNA is a precision medicine company based in Gosselies, Belgium, that provides molecular and proteomic analyses to guide cancer treatment decisions. Led by CEO Jean-Pol Detiffe, the company supports oncologists daily in finding treatment options for advanced cancer patients. Its product suite includes OncoDEEP (DNA sequencing and protein analyses of solid biopsies), OncoDEEP&TRACE (combined solid tumour and liquid biopsy analyses), OncoTRACE (a blood-based tumor monitoring solution), and OncoSHARE (sample logistics, ordering, process follow-up, data analysis and sharing). The company closed a €7.7M equity financing round and intends to use the proceeds to further accelerate global market expansion. No revenue or user metrics were disclosed in the article.

• Establishment Labs

  Led · Equity · Sep 2015

  Establishment Labs is a global, privately held medical technology company focused on aesthetic technologies and product innovation. Its core offering is the CE-marked Motiva Implants line of ultra-high purity medical-grade silicone breast implants, which are sold in more than 60 countries. The company also markets Divina, a proprietary 3D imaging technology for consultation and surgical planning, and distributes Puregraft, an FDA-cleared and CE-marked fat-purification technology. All of its manufacturing facilities are reported to be compliant with applicable FDA and ISO standards. Management says it will use financing to support R&D into next-generation implants, pursue expanded commercialization in markets where Motiva is approved, and back a proposed FDA trial and entrance into the U.S. market. The company closed a $55 million combined secured credit facility and equity investment to support these initiatives. Establishment Labs is an NYC-based global medical device company focused on breast surgery technologies, designing, developing, manufacturing and marketing advanced silicone-filled breast and body shaping implants. Its CE-marked Motiva Implants® line is sold in more than 60 countries worldwide. Puregraft® is an FDA-cleared and CE-marked technology that provides plastic surgeons with purified fat for reinjection on the sterile field. The company intends to use the $18M financing to launch Motiva Implants and Puregraft in some of the largest markets worldwide. Over the last six months the company has received regulatory clearances in Russia, Australia, Saudi Arabia, Israel, Vietnam and Brazil, among others. Establishment Labs is currently scaling up production capacity at its manufacturing plant in Costa Rica. Establishment Labs develops, manufactures and markets the CE-marked Motiva Implants® line and a portfolio of advanced silicone-filled breast and body shaping implants. The Motiva Implants® are manufactured in compliance with ISO and EU requirements and certified under Medical Device Directive 93/42/EEC. Led by CEO Juan José Chacón Quirós, the company is focused on expanding its Motiva Implants® in international markets. Establishment Labs secured up to $15m in debt funding to strengthen its financial position. The company plans to use the funds to finalize a new manufacturing facility and to start United States Food and Drug Administration trials. The financing supports both operational stability and product expansion efforts. Establishment Labs, based in Alajuela, Costa Rica and led by CEO Juan José Chacón-Quirós, designs, develops, manufactures and markets advanced silicone-filled breast and body shaping implants. Its CE-marked Motiva Implant Matrix® line is produced under ISO and EU requirements and is certified under Medical Device Directive 93/42/EEC. Motiva implants include features such as RFID microtransponders, fully biocompatible nanosurfaces, and TrueTissue™ dynamics and carry an extended product guarantee through Lloyd’s of London. Products are scrutinized by professional Quality Engineers throughout the manufacturing process. Thousands of patients and plastic surgeons in over 50 countries across five continents are using Motiva implants. The company closed a $20M financing round and intends to use the funds to accelerate investment in technology, grow its customer base, and scale the business.

• Genesis Media

  Participated · Series B · Apr 2014

  Genesis Media builds ContentUnlock, a data-driven decisioning platform that intercepts users with timed, targeted ads (typically video) to unlock publisher content. Publishers deploy ContentUnlock as an alternative to paywalls, requiring ad viewing for continued access with configurable gap periods (for example, seven articles, 24–48 hours, or one week). The product seeks to contextualize ads and vary frequency by reader behavior, showing fewer ads to loyal direct visitors and more aggressive monetization to referral traffic. Genesis counts American Media, Bonnier, USA Today Sports, and The Smithsonian among its publisher partners. The company says its business model is moving toward a platform approach, in some cases providing technology for publishers’ own sales teams rather than selling the ads directly. Financially, Genesis announced a $6 million Series B equity raise and said that including credit the round totaled $10 million. Genesis Media operates a video advertising platform focused on pairing the right video with the right viewer, once described as "the Match.com of video advertising." It was created by the November merger of AdGenesis and TVGenesis. Publishers in its network include Fox, Parade, and Conde Nast. The company says it reaches more than 150 million consumers and that 15 million U.S. users have opted in to its video ad platform. Genesis Media reports a 7 percent clickthrough rate on matched ads, 80 percent completion rates, and roughly 20 times more engagement than traditional video pre-rolls. The startup emphasizes innovative online video advertising tools and targeting to drive advertiser engagement as it scales publisher partnerships.

No current team members are available.